Purple Biotech (DE:1YI0)
FRANKFURT:1YI0
1YI0 Stock Chart & Stats
€0.28
€0.00(0.00%)
At close: 4:00 PM EST
€0.28
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.38
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€9.58M
Enterprise Value-€3.60M
Total Cash (Recent Filing)€6.43M
Total Debt (Recent Filing)€184.00K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Jul 30, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,621,046
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.94Price Target Upside9164.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated CAPTN-3 Platform & IM1240 Preclinical DataRobust preclinical efficacy and a capping design that materially improves PK and reduces cytokine release address core safety and exposure challenges for T-cell engagers. This structural advantage can widen the therapeutic window, improve clinical success odds, and make CAPTN-3 materially more partnerable over the next 2–6 months and beyond.
Strategic R&D Partnerships And Expert Advisory BoardIntegrating AI-driven molecule design and external clinical expertise strengthens discovery productivity and trial strategy. This durable capability can accelerate candidate quality and IND timelines, reduce development risk, and improve odds of attractive partnerships or licensing over the medium term.
Low Leverage And Maintained Nasdaq ListingA conservative debt profile lowers near-term bankruptcy risk and preserves financing optionality. Coupled with regained Nasdaq compliance, the company retains access to public capital and strategic partners, supporting execution of IND-enabling work and first-in-human plans without immediate debt pressure.
Bears Say
Persistent Negative Cash GenerationSustained negative operating and free cash flows mean the company must rely on external funding to advance programs. Over 2–6 months this structural cash burn increases dilution and execution risk, constraining resources for IND-enabling work or expanding trials without partners or new capital.
No Recurring Revenue And Sizable, Persistent LossesAs a clinical-stage biotech, lack of product revenue and recurring losses are structural until successful approvals or commercialization. Persistent negative earnings raise dependence on financing or partnerships and reduce margin resilience, limiting long-term self-funding capacity and increasing dilution risk.
Major Impairment Of Legacy Assets And Limited Cash RunwayA large impairment signals prior R&D investments failed to meet expectations, eroding equity and credibility of legacy programs. Combined with modest cash reserves and finite runway, this increases the likelihood of near-term fundraising, program reprioritization, or dependence on partnership deals that can dilute or shift strategy.
Purple Biotech News
1YI0 FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was €0.28 and its highest was €0.38 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is €9.58M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Jul 30, 2026 which is in 42 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on May 15, 2026. The company reported -€0.078 earnings per share for the quarter, beating the consensus estimate of -€0.328 by €0.25.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -0.84.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,621,046 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -€0.078 in its last earnings report, beating expectations of -€0.328. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in DE:1YI0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
1YI0 Stock 12 Month Forecast
Average Price Target
€25.94
▲(9164.11% Upside)
Options Prices
Currently, No data available
---